Unlike prostate cancer α radionuclide therapy ([225Ac]Ac-PSMA-617), xerostomia is rare in NET patients due to differing biodistribution, with much lower salivary gland uptake seen with the radiolabeled SSA in comparison to urea motif-based radiolabeled ligands for the prostate specific membrane antigen [50]. Here, FOLH1 is linked to xerostomia.